We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Novo also pointed to Tresiba’s ability to reduce the rate of severe hypoglycemia by 80% against Toujeo and pare down the rate of nocturnal hypoglycemia by 37% during that same 36-week period.
Novo Nordisk can add data showing Tresiba can reduce the risk of hypoglycaemia to its label, a development which should help its fight competition from cheaper alternatives.
Voluntis announced that Insulia, its digital companion for people with Type 2 diabetes, has received FDA clearance and the CE mark to integrate Basaglar and Tresiba.